Compare IPCA Labs with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs SUVEN LIFESCIENCES - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS SUVEN LIFESCIENCES IPCA LABS/
SUVEN LIFESCIENCES
 
P/E (TTM) x 23.5 21.5 109.1% View Chart
P/BV x 4.5 4.4 103.1% View Chart
Dividend Yield % 0.3 0.5 55.8%  

Financials

 IPCA LABS   SUVEN LIFESCIENCES
EQUITY SHARE DATA
    IPCA LABS
Mar-19
SUVEN LIFESCIENCES
Mar-19
IPCA LABS/
SUVEN LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs1,042338 308.6%   
Low Rs590169 348.3%   
Sales per share (Unadj.) Rs298.652.1 572.9%  
Earnings per share (Unadj.) Rs35.06.8 512.4%  
Cash flow per share (Unadj.) Rs49.48.6 576.9%  
Dividends per share (Unadj.) Rs3.001.50 200.0%  
Dividend yield (eoy) %0.40.6 62.1%  
Book value per share (Unadj.) Rs247.165.3 378.5%  
Shares outstanding (eoy) m126.35127.28 99.3%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.74.9 56.2%   
Avg P/E ratio x23.337.1 62.8%  
P/CF ratio (eoy) x16.529.6 55.8%  
Price / Book Value ratio x3.33.9 85.0%  
Dividend payout %8.622.0 39.0%   
Avg Mkt Cap Rs m103,10832,272 319.5%   
No. of employees `00013.41.1 1,242.3%   
Total wages/salary Rs m7,874661 1,190.9%   
Avg. sales/employee Rs Th2,807.06,132.2 45.8%   
Avg. wages/employee Rs Th585.8611.1 95.9%   
Avg. net profit/employee Rs Th329.0803.5 40.9%   
INCOME DATA
Net Sales Rs m37,7326,635 568.7%  
Other income Rs m577242 238.1%   
Total revenues Rs m38,3096,877 557.0%   
Gross profit Rs m6,9011,604 430.2%  
Depreciation Rs m1,824221 823.9%   
Interest Rs m18938 500.5%   
Profit before tax Rs m5,4651,587 344.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,042718 145.2%   
Profit after tax Rs m4,422869 508.6%  
Gross profit margin %18.324.2 75.6%  
Effective tax rate %19.145.2 42.2%   
Net profit margin %11.713.1 89.4%  
BALANCE SHEET DATA
Current assets Rs m23,7786,232 381.5%   
Current liabilities Rs m10,9751,490 736.5%   
Net working cap to sales %33.971.5 47.5%  
Current ratio x2.24.2 51.8%  
Inventory Days Days10486 120.0%  
Debtors Days Days6683 79.8%  
Net fixed assets Rs m20,3684,043 503.7%   
Share capital Rs m253127 198.5%   
"Free" reserves Rs m30,9718,183 378.5%   
Net worth Rs m31,2248,310 375.7%   
Long term debt Rs m1,40918 7,912.9%   
Total assets Rs m45,50710,389 438.0%  
Interest coverage x30.043.1 69.5%   
Debt to equity ratio x00 2,105.9%  
Sales to assets ratio x0.80.6 129.8%   
Return on assets %10.18.7 116.0%  
Return on equity %14.210.5 135.4%  
Return on capital %17.319.5 88.8%  
Exports to sales %45.90-   
Imports to sales %16.60-   
Exports (fob) Rs m17,308NA-   
Imports (cif) Rs m6,266NA-   
Fx inflow Rs m17,3085,622 307.9%   
Fx outflow Rs m6,2661,799 348.2%   
Net fx Rs m11,0423,822 288.9%   
CASH FLOW
From Operations Rs m4,923356 1,384.8%  
From Investments Rs m-1,563-279 561.1%  
From Financial Activity Rs m-1,832-225 813.9%  
Net Cashflow Rs m1,528-148 -1,030.8%  

Share Holding

Indian Promoters % 45.9 63.4 72.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 0.0 -  
FIIs % 25.3 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 36.5 47.7%  
Shareholders   36,892 37,287 98.9%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  PROCTER & GAMBLE HEALTH  GSK PHARMA  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Nov 15, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS